Minister for Health and Medical Education, Social Welfare and Education, Sakeena Itoo, today chaired a meeting at Civil ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The recall affects 4 oz. bottles of the natural cough syrup distributed across the United States between December 2022 and ...

An FDA pilot program, known as the Commissioner’s Priority Voucher program, could drastically change the way pharmaceutical ...

In a research paper published in The Lancet HIV this week, experts found that generic lenacapavir could cost $35-$46 per ...

Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

On Tuesday, the U.S. Food and Drug Administration announced a new initiative to offer expedited reviews for new medicines, an ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

The drug, known as Yeztugo, is the first and only twice-yearly option available in the U.S. for people who need or want PrEP, Gilead said Wednesday. Just under 100% of patients who received the drug ...